In second oral presentation, Hemab presented first preclinical data for HMB-002, a potential novel treatment for Von Willebrand Disease Results from lived experience of Glanzmann thrombasthenia (GT360 ...
The Phase 2 study consists of a minimum 6-week prospective run-in where participants record bleeds via an electronic bleed diary, followed by 3 months of treatment with HMB-001. Interim efficacy data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results